Cannabis Industry Leaders React To DEA’s Historic Move To Reschedule Cannabis
In a landmark decision, the U.S. Drug Enforcement Administration (DEA) is reportedly moving cannabis from Schedule I to Schedule III under the Controlled Substances Act, sparking varied reactions across the industry.
MariMed’s (OTC:MRMD) Enthusiastic Endorsement Bob Fireman, CEO of MariMed, expressed his excitement about the decision: “The impending announcement of the DEA’s decision to recategorize cannabis…is historic. The positive impact this will have cannot be overstated. Our industry, the millions of consumers and patients we serve, and the individuals and communities that have been ravaged by the War on Drugs, all will see positive benefits.”
Vicente LLP Highlights Medical Recognition Shawn Hauser, Partner at Vicente LLP, emphasized the significance of the FDA’s acknowledgment: “FDA’s acknowledgment of the medical efficacy of cannabis and …